Peptide LibraryLanreotide dosage in published studies and labels
These are the doses used for Lanreotide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Lanreotide has FDA-approved human dosages. Somatuline Depot for acromegaly starts at 90 mg by deep injection under the skin every 4 weeks for 3 months, then is adjusted to 60, 90 or 120 mg. For gastroenteropancreatic neuroendocrine tumors and for carcinoid syndrome it is 120 mg every 4 weeks.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 60–120 mg every 4 weeks, by indication |
| Route | Subcutaneous |
| Frequency | Every 4 weeks |
| Duration studied | Long-term |
| Titration | Acromegaly: 90 mg for 3 months, then 90 mg kept, raised to 120 mg or lowered to 60 mg by GH, IGF-1 and symptoms. 60 mg to start with moderate or severe kidney or liver impairment. |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Somatuline Depot, acromegalyFDA-approved label · FDA prescribing information | Adults with acromegaly with an inadequate response to, or who cannot have, surgery or radiotherapy | Start 90 mg for 3 months; then 60, 90 or 120 mg by GH, IGF-1 and symptoms. Start 60 mg with moderate or severe renal or hepatic impairment | Deep subcutaneous, prefilled syringe | Every 4 weeks | Long-term | GH and IGF-1 control | SOMATULINE DEPOT (lanreotide) injection — FDA prescribing information, DailyMed |
| FDA label — Somatuline Depot, GEP-NETsFDA-approved label · FDA prescribing information | Adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors | 120 mg | Deep subcutaneous | Every 4 weeks | Long-term | Improved progression-free survival | SOMATULINE DEPOT (lanreotide) injection — FDA prescribing information, DailyMed |
| FDA label — Somatuline Depot, carcinoid syndromeFDA-approved label · FDA prescribing information | Adults with carcinoid syndrome | 120 mg (no extra dose if already treated for GEP-NETs) | Deep subcutaneous | Every 4 weeks | Long-term | Less use of short-acting somatostatin analog rescue therapy | SOMATULINE DEPOT (lanreotide) injection — FDA prescribing information, DailyMed |
Where sources disagree
- Generic lanreotide injections from other labellers are also listed on DailyMed; the doses here are from the originator Somatuline Depot label.
- The label warns about gallstones, high or low blood sugar, slower heart rate and reduced thyroid function.